Previous 10 | Next 10 |
10-target partnership leverages AbCellera’s technology to accelerate Everest’s pipeline of novel, innovative medicines to patients AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced today that they h...
Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA Participating EU/EEA countries can purchase bamlanivimab together with etesevimab directly from Lilly foll...
4 Top Biotech Stocks To Watch This Upcoming Week As the broader stock market continues to show signs of caution, biotech stocks continue to offer their high-risk, high-reward potential. Biotech is a multi-billion industry with countless trials and FDA approvals involved. Each st...
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...
Stock Futures Edging Down Ahead Of Fresh Data On Consumer Sentiment Stock futures were under pressure yet again on Friday morning as investors evaluated the resilience of global economic recovery. From the prospect of Fed tapering to the debt crisis at China Evergrande Group, invest...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! There’s only one day of trading left so let’s start it off right with a look at the biggest pre-market stock movers for Friday. Source: ventdusud / Shutterstock.com We’re s...
Emergency use authorization now includes post-exposure prophylaxis to prevent COVID-19 in certain people who have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting AbCellera (Nasdaq: ABCL) today announced the...
Shares of AbCellera Biologics (NASDAQ: ABCL) closed 7.1% higher today following news of a new partnership with Moderna (NASDAQ: MRNA) , one of the first names to develop an effective COVID-19 vaccine. Moderna has been given much of the credit for coming up with its vacci...
Partnership combines AbCellera’s AI-powered antibody discovery platform with Moderna’s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications AbCellera (Nasdaq: ABCL) announced today that it ...
AbCellera (ABCL -5.7%) acquires TetraGenetics, a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins. It will be an all-cash transaction that includes an upfront payment, the potential for payments based on...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...